PharmTech Drug Digest 11.20
|Articles|September 30, 2013

Greiner Bio-One GmbH

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory products. The company is a technology partner for universities, hospitals, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well.

Greiner Bio-One GmbH

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory products. The company is a technology partner for universities, hospitals, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well.

Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 364 million euros. It has over 1,700 employees and operates globally with 24 subsidiaries and numerous distributors in more than 100 countries.

Greiner Bio-One is a leading supplier of special products for cell cultures and microplates for high-throughput screening and a developer of innovative biochips and sample collection systems. The company performs contract work from the pharmaceutical industry, the diagnostic and medical sectors. Greiner Bio-One uses injection moulding to produce a whole range of customised plastic platforms for the life sciences sector and offers the complete product development and production process from the idea through to the finished product. The company produces small and large series, undertakes customer-specific branding and can call on production facilities in Europe, the U.S. and Asia.

Visit us at CPhI/ICSE/P-MEC Hall and stand number: Hall 4.1, Booth No. 41H09

Greiner Bio-One GmbH

Bad Haller Strasse 32, 4550 Kremsmuenster, Austria

Telephone: +43 7583 67910       Fax:  +43 7583 6318

E-mail: office@at.gbo.com

Website: www.gbo.com

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.